Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

This study combines two targeted drugs — blinatumomab and asciminib — to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a type of blood cancer driven by a specific genetic abnormality. The trial aims to find out whether this combination can help patients who are newly diagnosed, relapsed, or not responding to existing therapies. **You may be eligible if...** - You are 12 years or older and have been diagnosed with Ph+ ALL (a specific type of leukemia caused by the Philadelphia chromosome) - You are newly diagnosed and not suitable for intensive chemotherapy, OR your leukemia has returned or is not responding to previous treatment - You weigh at least 40 kg - Your liver and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have active, uncontrolled cancer that has spread to the brain or spinal cord - You have serious heart conditions - You are pregnant or breastfeeding - You have an active, uncontrolled infection Talk to your doctor to see if this trial is right for you.